Coronary Stents Pipeline Report Including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update
Summary
GlobalData's Medical Devices sector report, “Coronary Stents Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update provides comprehensive information about the Coronary Stents pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
A stent is an expandable perforated tube that is inserted into a natural conduit of the body to prevent or counteract a disease-induced localized flow constriction.
Note:Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Scope
Extensive coverage of the Coronary Stents under development
The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
The report reviews the major players involved in the development of Coronary Stents and list all their pipeline projects
The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
The report provides key clinical trial data of ongoing trials specific to pipeline products
Recent developments in the segment / industry
Reasons to Buy
The report enables you to -
Formulate significant competitor information, analysis, and insights to improve R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
Identify and understand important and diverse types of Coronary Stents under development
Develop market-entry and market expansion strategies
Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
In-depth analysis of the product’s current stage of development, territory and estimated launch date
1 Table of Contents
1 About GlobalData
2 Table of Contents
2.1 List of Tables
2.2 List of Figures
3 Introduction
3.1 Coronary Stents Overview
4 Products under Development
4.1 Coronary Stents - Pipeline Products by Stage of Development
4.2 Coronary Stents - Pipeline Products by Segment
4.3 Coronary Stents - Pipeline Products by Territory
4.4 Coronary Stents - Pipeline Products by Regulatory Path
4.5 Coronary Stents - Pipeline Products by Estimated Approval Date
4.6 Coronary Stents - Ongoing Clinical Trials
5 Coronary Stents - Pipeline Products under Development by Companies
5.1 Coronary Stents Companies - Pipeline Products by Stage of Development
5.2 Coronary Stents – Companies Pipeline Products by Stage of Development
Table 23: Xience SBA Everolimus Eluting Coronary Stent System - A Multi-center, Randomized, Controlled Trial to Demonstrate the Safety and Effectiveness of the MiStent II for the Revascularization of Coronary Arteries: CRYSTAL Study
Table 24: Xience SBA Everolimus Eluting Coronary Stent System - A Prospective, Multi-center, Single-blinded, Randomized Trial of the Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System in Patients with Coronary Artery Disease: IRONMAN-II
Table 25: Xience SBA Everolimus Eluting Coronary Stent System - Intracoronary Stenting and Restenosis - Randomized Trial of Drug-eluting Stent Implantation or Drug-coated Balloon Angioplasty According to Neointima Morphology in Drug-eluting Stent Restenosis 5
Table 71: Biosensors International Group Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 72: BioFreedom Ultra - Product Status
Table 73: BioFreedom Ultra - Product Description
Table 74: Sparrow Drug Eluting Stent System - Product Status
Table 75: Sparrow Drug Eluting Stent System - Product Description
Table 76: Biosensors International Group Ltd - Ongoing Clinical Trials Overview
Table 77: BioFreedom Ultra - A Pilot Study Registry of the BioFreedom BA9 Ultra Drug-Coated Coronary Stent for Patients With ST Elevation Myocardial Infarct (STEMI) Undergoing Percutaneous Coronary Intervention (PCI)
Table 78: BioFreedom Ultra - A Post-Market Registry of the BioFreedom Ultra CoCr Biolimus A9 Coated Coronary Stent System
Table 79: BioFreedom Ultra - A Prospective Multicenter Single Arm Trial to Assess the Safety and Effectiveness of Additional Sizes of the BioFreedom Ultra CoCr Biolimus A9 Coated Coronary Stent System
Table 80: BioFreedom Ultra - A Prospective Study of the BioFreedom Biolimus A9 Drug Coated Stent in Patients at High Risk for Bleeding
Table 81: BioFreedom Ultra - A Randomized Controlled Comparison Between One Versus More than Six Months of Dual Antiplatelet Therapy after Biolimus A9-eluting Stent Implantation
Table 82: BioFreedom Ultra - Asian Registry of the BioFreedom BA9 Drug-Coated Coronary Stent for Patients with ST Elevation Myocardial Infarction (STEMI) Undergoing Percutaneous Coronary Intervention (PCI)
Table 83: BioFreedom Ultra - BioFreedom Ultra Stent in Hong Kong All Comers Registry
Table 84: BioFreedom Ultra - Comparison of Polymer-free Cobalt-Chromium Thin Drug-coated Stents with Biodegradable Polymer Ultrathin Sirolimus-Eluting Stents and Prasugrel Monotherapy with Conventional 12-Month Dual Antiplatelet Therapy
Table 85: BioFreedom Ultra - Evaluation of Effectiveness and Safety of Biofreedom Family Stent in Routine Clinical Practice; A Multicenter, Prospective Observational Study
Table 86: BioFreedom Ultra - Evaluation of Effectiveness and Safety of the First, Second, and New Drug-eluting Stents in Routine Clinical Practice
Table 87: BioFreedom Ultra - P2Y12 Inhibitor-based Single Antiplatelet Therapy Versus Conventional Dual Antiplatelet Therapy After Percutaneous Coronary Intervention With BioFreedom Ultra Drug-coated Stent for Unprotected Left Main Coronary Artery Disease (ULTRA-LM)
Table 88: BioFreedom Ultra - Randomized Comparison of a Polymer-free Biolimus-eluting BioFreedom Stent with a Biodegradable-polymer Sirolimus-eluting Orsiro Stent in Patients Treated with Percutaneous Coronary Intervention
Table 89: BioFreedom Ultra - Randomized Comparison of Vascular Healing of a Polymer-free Biolimus-eluting BIOFREEDOM Stent with a Biodegradable-polymer Sirolimus-eluting ORSIRO Stent in Patients with ST-segment Elevation Myocardial Infarction 6
Table 100: Biotronik AG - Ongoing Clinical Trials Overview
Table 101: Magmaris Bioresorbable Magnesium Scaffold - A Sirolimus Eluting Bioresorbable Magnesium Stent for Treatment of Coronary Bifurcation Lesions: The BIFSORB Pilot Study II
Table 102: Magmaris Bioresorbable Magnesium Scaffold - BIOTRONIK - Safety and Clinical Performance of the Drug Eluting Absorbable Metal Scaffold (DREAMS 2nd Generation) in the Treatment of Subjects with de Novo Lesions in Native Coronary Arteries: BIOSOLVE-II
Table 103: Magmaris Bioresorbable Magnesium Scaffold - Biotroniks - Safety and Performance in de Novo Lesion of Native Coronary Arteries with Magmaris- Registry: BIOSOLVE-IV
Table 104: Magmaris Bioresorbable Magnesium Scaffold - Coronary Artery Healing Process after Bioresorbable Scaffold in Patients with Non-ST-segment Elevation Myocardial Infarction (NSTEMI)
Table 105: Magmaris Bioresorbable Magnesium Scaffold - Optical Coherence Guided Treatment of ST-segment Elevation Myocardial Infarction with the Drug-eluting Resorbable Magnesium Scaffold: The BEST- MAG Multicentre Study (Belgian ST-segment Elevation Myocardial Infarction Treatment with Resorbable Magnesium Scaffold)
Table 106: Magmaris Bioresorbable Magnesium Scaffold - Retrospective, Observational Register to Investigate the Procedural and Post Procedural Implantation of Bioabsorbable Magnesium Scaffolds Magmaris (MAGIC Registry)
Table 109: DREAMS 3G System - BIOTRONIK - Safety and Clinical Performance of the - Sirolimus-Eluting Resorbable Coronary Magnesium Scaffold System (DREAMS 3G) in the Treatment of Subjects with de Novo Lesions in Native Coronary Arteries
Table 110: DREAMS 3G System - BIOTRONIK - Safety and Clinical Performance of the Drug Eluting Resorbable Coronary Magnesium Scaffold System (DREAMS 3G) in the Treatment of Subjects with de Novo Lesions in Native Coronary Arteries: BIOMAG-II: A Randomized Controlled Trial
Table 111: Biotronik SE & Co KG Pipeline Products & Ongoing Clinical Trials Overview 6
Table 112: AMS-2 - Product Status 6
Table 113: AMS-2 - Product Description 6
Table 114: ProGenic Pimecrolimus-eluting Coronary Stent System - Product Status 7
Table 116: Biotyx Medical (Shenzhen) Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 117: IBS Angel - Product Status
Table 118: IBS Angel - Product Description
Table 119: Biotyx Medical (Shenzhen) Co Ltd - Ongoing Clinical Trials Overview
Table 120: IBS Angel - A Prospective, Multi-center, Single-arm Clinical Trial to Evaluate the Safety and Efficacy of Iron Bioresorbable Scaffold System (IBS Angel) in Patients with Pulmonary Artery Stenosis